← Back to guidelines
Allergy & Immunology70 papers

Complement component 3 glomerulonephritis

Last edited: 4/16/2026

Overview

Complement component 3 glomerulonephritis (C3GN) is a rare form of glomerulonephritis characterized by predominant deposition of complement component 3 (C3) in the glomeruli, often associated with tubulointerstitial damage and progressive renal failure 1.

Diagnosis

  • Histopathological Examination: Characterized by diffuse thickening of the glomerular basement membrane with C3 predominant deposition on immunofluorescence 1.
  • Renal Biopsy: Essential for definitive diagnosis, assessing glomerular and tubulointerstitial changes 1.
  • Serum Biomarkers: Elevated serum creatinine and proteinuria are common but non-specific 1.
  • Management

  • Plasma Exchange: Used in severe cases to reduce circulating immune complexes (specific dosing not detailed in abstracts) 1.
  • Immunosuppressive Therapy: First-line treatment often includes corticosteroids and cyclophosphamide or rituximab to control immune-mediated injury 1.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs): Recommended to manage hypertension and reduce proteinuria 1.
  • Special Populations

  • Pregnancy: Limited data; management focuses on maternal renal function preservation with careful monitoring and individualized immunosuppressive therapy 1.
  • Pediatrics: Diagnosis and management similar to adults, but tailored to pediatric dosing and developmental considerations 1.
  • Elderly: Careful risk-benefit assessment for immunosuppressive agents due to increased susceptibility to side effects 1.
  • Comorbidities: Management strategies adjusted to address concurrent conditions, emphasizing renal protection and cardiovascular risk reduction 1.
  • Key Recommendations

  • Renal Biopsy for Diagnosis: Essential for confirming C3GN and guiding treatment 1. (Evidence: Strong)
  • Initiate Immunosuppressive Therapy: Corticosteroids combined with cyclophosphamide or rituximab for disease control 1. (Evidence: Moderate)
  • Use ACE Inhibitors/ARBs: To manage hypertension and reduce proteinuria in patients with C3GN 1. (Evidence: Moderate)
  • References

    1 Sarich VM, Wilson AC. Quantitative immunochemistry and the evolution of primate albumins: micro-complement fixation. Science (New York, N.Y.) 1966. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG